By Virtual Copywriting Services
On the heels of writing at least three articles within the past two months on the M&A freezy, today we see yet another exciting deal. This one, the pharmaceuticals company Sanofi-Aventis (SNY) has agreed to pay $4 billion in cash to U.S. drugmaker Merck & Co. Inc. (MRK) for its share in the two companies' animal health joint venture Merial.
Sanofi-Aventis will own all of Merial, a joint venture it set up with Merck in 1997, following completion of the deal, expected in the fourth quarter. Once Merck and Schering-Plough complete their merger, Sanofi-Aventis has the option of combining Merial with Schering-Plough's animal health business in a joint venture owned by Sanofi-Aventis and the new Merck, the companies. Schering-Plough (SGP) sells more than 15 animal medicine products, including antibiotics, fertility treatments and a number of vaccines for livestock; de-worming treatments for multiple animals; vaccines and treatments for ear infections and diabetes for dogs and cats, and the HomeAgain pet recovery system. The unit had sales of $630 million in the first quarter.
The potential combination would create a new leader in this $19 billion global animal health market. Merial sells some popular pet medicines -- flea-and-tick blocker Frontline and chewable heartworm preventer Heartgard -- plus Ivomec, which kills parasites in hogs and cattle. The venture had $684 million in first-quarter sales.
For information on new media content writing, SEO content, and web copywriting services visit http://www.sustainablevirtualbiz.com/ or call (503) 621-4953.
On the heels of writing at least three articles within the past two months on the M&A freezy, today we see yet another exciting deal. This one, the pharmaceuticals company Sanofi-Aventis (SNY) has agreed to pay $4 billion in cash to U.S. drugmaker Merck & Co. Inc. (MRK) for its share in the two companies' animal health joint venture Merial.
Sanofi-Aventis will own all of Merial, a joint venture it set up with Merck in 1997, following completion of the deal, expected in the fourth quarter. Once Merck and Schering-Plough complete their merger, Sanofi-Aventis has the option of combining Merial with Schering-Plough's animal health business in a joint venture owned by Sanofi-Aventis and the new Merck, the companies. Schering-Plough (SGP) sells more than 15 animal medicine products, including antibiotics, fertility treatments and a number of vaccines for livestock; de-worming treatments for multiple animals; vaccines and treatments for ear infections and diabetes for dogs and cats, and the HomeAgain pet recovery system. The unit had sales of $630 million in the first quarter.
The potential combination would create a new leader in this $19 billion global animal health market. Merial sells some popular pet medicines -- flea-and-tick blocker Frontline and chewable heartworm preventer Heartgard -- plus Ivomec, which kills parasites in hogs and cattle. The venture had $684 million in first-quarter sales.
For information on new media content writing, SEO content, and web copywriting services visit http://www.sustainablevirtualbiz.com/ or call (503) 621-4953.
No comments:
Post a Comment